NasdaqHealth CareHealth Care ServicesS&P SmallCap 600
$13.77
+0.34 (+2.53%)
Close of Nov 06, 2026 · end-of-day data
LFST 8-K filings in 2026
Every material Form 8-K Lifestance Health filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
LifeStance reported third quarter 2026 revenue of $455.9 million, up 25%, and net income of $22.4 million, compared with $1.1 million a year earlier. The company raised its full-year 2026 guidance for revenue, Center Margin and Adjusted EBITDA, which points to stronger expected results for shareholders.
Q3 2026 revenue $455.9 million, up 25% from $363.8 million; net income $22.4 million versus $1.1 million
Adjusted EBITDA $68.4 million, up 70%; Center Margin $161.4 million, up 38%
Full-year 2026 revenue guidance raised to $1.741 billion to $1.761 billion; Adjusted EBITDA to $242 million to $250 million
Q4 2026 guidance: revenue $446 million to $466 million; Adjusted EBITDA $56 million to $64 million
LifeStance Health Group disclosed that director Teresa DeLuca, M.D., notified the board on October 14, 2026, of her resignation from the board and all of its committees, effective December 31, 2026. The company states the resignation is not the result of any disagreement with the company.
Teresa DeLuca, M.D., resigns from the board of directors and all committees.
Resignation notified to the board on October 14, 2026, effective December 31, 2026.
Company states the resignation does not result from any disagreement with Dr. DeLuca.
Filing does not name a replacement director or describe any financial effect.
LifeStance Health Group reported second-quarter 2026 revenue of $435.4 million, up 26%, and net income of $23.6 million, compared with a net loss of $3.8 million a year earlier. The company raised its full-year 2026 revenue, Center Margin and Adjusted EBITDA guidance and approved a new $100 million share repurchase program, which replaces its prior $100 million program from February 24, 2026.
Q2 2026 revenue was $435.4 million, up 26% from $345.3 million; net income was $23.6 million versus a net loss of $3.8 million in Q2 2025.
Adjusted EBITDA rose 94% to $66.0 million, or 15.2% of total revenue, compared with $34.0 million a year earlier.
Full-year 2026 revenue guidance was raised to $1.685 billion to $1.725 billion, and Adjusted EBITDA guidance is $215 million to $235 million.
The Board approved a $100 million share repurchase program on August 5, 2026, replacing the prior $100 million program approved February 24, 2026.
LifeStance Health Group said director Jeffrey Rhodes resigned from the board and all its committees effective immediately, and that the resignation was not due to any disagreement with the company. The board appointed Thurman Justice, Lori Goltermann and Safwan Shabab as directors to fill vacancies, a board change that is administrative in nature and carries no stated financial effect.
Jeffrey Rhodes resigned from the board and all committees effective immediately, notified July 2, 2026
Thurman Justice and Lori Goltermann appointed Class II directors, serving until the 2029 annual meeting
Safwan Shabab appointed Class III director under a June 9, 2021 stockholder agreement, serving until the 2027 meeting
Justice and Goltermann each received an initial award of 35,492 restricted stock units under the 2021 Equity Incentive Plan
LifeStance Health Group reported first-quarter 2026 revenue of $403.5 million, up 21%, and net income of $14.2 million, compared with $0.7 million a year earlier. The company raised its full-year 2026 revenue, Center Margin and Adjusted EBITDA guidance, which signals higher expected earnings for shareholders.
Q1 2026 revenue was $403.5 million, up 21% from $333.0 million; Adjusted EBITDA rose 48% to $51.1 million
Net income was $14.2 million, versus $0.7 million in Q1 2025; diluted EPS was $0.04 versus $0.00
Full-year 2026 revenue guidance raised to $1.640 billion to $1.680 billion, from $1.615 billion to $1.655 billion
Full-year 2026 Adjusted EBITDA guidance raised to $200 million to $220 million, from $185 million to $205 million
LifeStance Health Group promoted Lisa Miller, previously its Executive Vice President of Practice Operations, to Chief Operating Officer and Principal Operating Officer, effective March 10, 2026. The filing sets her base salary at $485,000 and a 2026 bonus target of 85% of base salary, plus an annual equity award with a target grant date value of about $1.5 million.
Lisa Miller, age 52, promoted to Chief Operating Officer and Principal Operating Officer on March 10, 2026
Annual base salary of $485,000 with a bonus target of 85% of base salary beginning in calendar 2026
Annual equity award of about $1.5 million target grant date value, split between time-based and performance-based restricted stock units
LifeStance reported fourth-quarter 2025 revenue of $382.2 million, up 17%, and net income of $11.7 million, compared with a net loss a year earlier, and issued 2026 guidance for revenue of $1.615 billion to $1.655 billion. The Board also approved a share repurchase program of up to $100 million and announced that Executive Chairman Kenneth Burdick will become non-executive Chairman effective March 16, 2026.
Q4 2025 revenue was $382.2 million, up 17%; full year revenue was $1,424.3 million, up 14%.
Q4 2025 net income was $11.7 million, versus a net loss of $7.1 million in Q4 2024; full year net income was $9.7 million.
2026 guidance: revenue of $1.615 billion to $1.655 billion and Adjusted EBITDA of $185 million to $205 million.
Board approved a repurchase program of up to $100 million of common stock; Kenneth Burdick moves to non-executive Chairman effective March 16, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Lifestance Health filing is on SEC EDGAR ↗. 8-K briefs of other companies →